Description: Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through Poultry Healthcare, Animal Healthcare, and Petcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers livestock vaccines for goat pox, peste des petits ruminants, brucella abortus, contagious bovine pleuropneumonia, CCPP, and lumpy skin diseases; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, coat nutrition, grooming aids, and anti-infective formulations. Additionally, the company provides seroprofiling kits; diagnostic labs for poultry flocks; and mastitis control programs for cattle; as well as engages in manufacturing and trading of goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.
Home Page: www.hester.in
Pushpak
Ahmedabad,
380006
India
Phone:
91 79 2644 5107
Officers
Name | Title |
---|---|
Mr. Rajiv Dinesh Gandhi B.Com | Executive CEO, MD & Executive Director |
Ms. Priya Gandhi | Executive Director |
Mr. Divyesh Maru | Chief Financial Officer |
Dr. Ram Prakash | Senior VP of Sales & Marketing and COO |
Mr. Vinod Mali | Company Secretary & Compliance Officer |
Dr. Sulochana Shrestha | CEO of Hester Biosciences Nepal Private Limited |
Dr. Upendra K. Jani | Consultant |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 0 |
---|---|
Trailing PE: | 92.608 |
Price-to-Book MRQ: | 7.1908 |
Price-to-Sales TTM: | 6.8611 |
IPO Date: | |
Fiscal Year End: | March |
Full Time Employees: | 642 |